BRPI0509420A - método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico - Google Patents
método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênicoInfo
- Publication number
- BRPI0509420A BRPI0509420A BRPI0509420-8A BRPI0509420A BRPI0509420A BR PI0509420 A BRPI0509420 A BR PI0509420A BR PI0509420 A BRPI0509420 A BR PI0509420A BR PI0509420 A BRPI0509420 A BR PI0509420A
- Authority
- BR
- Brazil
- Prior art keywords
- agent treatment
- reducing
- inhibiting angiogenesis
- antiangiogenic agent
- increasing efficacy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
"MéTODO DE REDUçãO OU INIBIçãO DA ANGIOGêNESE E MéTODO DE AUMENTO DA EFICáCIA DE TRATAMENTO COM AGENTE ANTIANGIOGêNICO". A presente invenção fornece métodos de uso de antagonista de EGFL7 para modular o desenvolvimento vascular. Também são fornecidos no presente métodos de seleção de moduladores da atividade de EGFL7. Além disso, são fornecidos métodos de tratamento utilizando antagonistas de EGFL7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56205404P | 2004-04-14 | 2004-04-14 | |
PCT/US2005/013658 WO2005117968A2 (en) | 2004-04-14 | 2005-04-14 | Compositions and methods comprising an egfl7 antagonist for modulating vascular development |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509420A true BRPI0509420A (pt) | 2007-09-04 |
Family
ID=35355481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509420-8A BRPI0509420A (pt) | 2004-04-14 | 2005-04-14 | método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico |
Country Status (14)
Country | Link |
---|---|
US (3) | US20070031437A1 (pt) |
EP (1) | EP1734998A2 (pt) |
JP (3) | JP5599136B2 (pt) |
KR (1) | KR101227817B1 (pt) |
CN (2) | CN102895663A (pt) |
AU (1) | AU2005249377A1 (pt) |
BR (1) | BRPI0509420A (pt) |
CA (1) | CA2563445C (pt) |
IL (2) | IL178329A0 (pt) |
MX (1) | MXPA06011851A (pt) |
NZ (1) | NZ550110A (pt) |
RU (3) | RU2365382C2 (pt) |
WO (1) | WO2005117968A2 (pt) |
ZA (1) | ZA200608615B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ550110A (en) | 2004-04-14 | 2009-09-25 | Genentech Inc | Compositions and methods comprising an EGFL7 antagonist for modulating vascular development |
AR059851A1 (es) * | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
SG172696A1 (en) | 2006-06-12 | 2011-07-28 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
WO2008010986A2 (en) * | 2006-07-17 | 2008-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of modulating angiogenesis |
WO2008130719A1 (en) * | 2007-04-24 | 2008-10-30 | University Of Louisville | Therapeutic beta-glucan combinations |
JP2009005584A (ja) * | 2007-06-26 | 2009-01-15 | Miyazaki Prefecture | ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞 |
BRPI0905660A2 (pt) * | 2008-01-14 | 2015-07-07 | Genentech Inc | "método para reduzir ou inibir a angiogênese" |
WO2010034155A1 (zh) * | 2008-09-25 | 2010-04-01 | 中南大学湘雅医院 | 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒 |
MX2011010570A (es) | 2009-05-08 | 2011-10-19 | Genentech Inc | Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos. |
JP6095367B2 (ja) * | 2009-07-13 | 2017-03-15 | ジェネンテック, インコーポレイテッド | 癌治療のための診断方法および組成物 |
WO2011084750A1 (en) * | 2009-12-21 | 2011-07-14 | Genentech, Inc. | Antibody formulation |
WO2013061112A1 (en) | 2011-10-24 | 2013-05-02 | Centre National De La Recherche Scientifique | Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium |
US9789213B2 (en) | 2012-03-27 | 2017-10-17 | London Health Sciences Centre Research Inc. | EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis |
US20170007495A1 (en) * | 2013-11-21 | 2017-01-12 | Mfr Products, Inc. | Therapeutic device to assist in myofascial release, and method of use |
EP3209681A4 (en) * | 2014-10-23 | 2018-10-31 | NGM Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
CN105543183B (zh) * | 2016-01-08 | 2019-04-12 | 吴帆 | 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用 |
CA3061505A1 (en) | 2017-04-24 | 2018-11-01 | Ohio State Innovation Foundation | Recombinant egfl7, egfl7 antibodies, and uses thereof |
RU2678200C1 (ru) * | 2018-07-27 | 2019-01-24 | Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" | Лекарственная пленка пролонгированного действия и способ её получения |
WO2022025783A1 (ru) | 2020-07-28 | 2022-02-03 | Общество с ограниченной ответственностью "Ангиолайф" | Применения комбинации генов ангиогенных и нейротрофических факторов |
CN114410642B (zh) * | 2021-12-31 | 2023-01-17 | 苏州大学 | 一种急性t淋巴细胞白血病药物靶点及其应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0248088A4 (en) * | 1985-11-22 | 1988-05-03 | Teijin Ltd | VASCULARIZATION FACTOR AND MANUFACTURING. |
WO1988001166A1 (en) | 1986-08-18 | 1988-02-25 | Biota Scientific Management Pty Ltd | Stimulation of angiogenesis and promotion of endothelialisation |
WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
IL133582A0 (en) * | 1997-06-18 | 2001-04-30 | Zymogenetics Inc | Mammalian neuro-growth factor like protein |
US20030166907A1 (en) * | 1997-06-18 | 2003-09-04 | Zymogenetics, Inc. | Mammalian neuro-growth factor like protein |
US5972338A (en) | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
US20030166108A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030050240A1 (en) | 1997-10-17 | 2003-03-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030069178A1 (en) | 1997-10-17 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7105640B2 (en) | 1997-10-17 | 2006-09-12 | Genentech, Inc. | Anti-pro792 antibodies |
US6974696B2 (en) | 1997-10-17 | 2005-12-13 | Genentech, Inc. | PRO853 nucleic acids |
US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
US20030039648A1 (en) | 1998-09-16 | 2003-02-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
ES2312205T3 (es) * | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
US7371836B2 (en) | 1998-03-27 | 2008-05-13 | Genentech, Inc. | PRO526 nucleic acids |
US7202338B2 (en) | 1998-03-31 | 2007-04-10 | Genentech, Inc. | PRO731 polypeptides |
US7166700B2 (en) | 1998-04-01 | 2007-01-23 | Genentech, Inc. | PRO703 Polypeptides |
US6962797B2 (en) | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
DE19817946A1 (de) | 1998-04-17 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe |
AU3965799A (en) | 1998-04-23 | 1999-11-08 | Millennium Pharmaceuticals, Inc. | Novel molecules of the t125-related protein family and uses thereof |
US7067636B2 (en) | 1998-05-06 | 2006-06-27 | Genentech, Inc. | Anti-pro 1017 antibodies |
US20030186368A1 (en) | 1998-05-13 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
US7019115B2 (en) | 1998-05-22 | 2006-03-28 | Genentech, Inc. | Pro1017 polypeptides |
US7220835B2 (en) | 1998-07-30 | 2007-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030203446A1 (en) | 1998-10-07 | 2003-10-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001054477A2 (en) | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
EP1135494A2 (en) | 1998-12-11 | 2001-09-26 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2596700A (en) | 1999-03-08 | 2000-09-28 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
JP2004507202A (ja) | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」 |
EP2028577A2 (en) | 1999-04-16 | 2009-02-25 | Fujikin Incorporated | Parallel bypass type fluid feeding device, and method and device for controlling fluid variable type pressure system flow rate used for the device |
US7214656B2 (en) | 1999-04-28 | 2007-05-08 | Genentech, Inc. | PRO792 polypeptides |
WO2001002563A2 (en) | 1999-07-02 | 2001-01-11 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
US7589172B2 (en) | 1999-07-20 | 2009-09-15 | Genentech, Inc. | PRO256 polypeptides |
TWI265167B (en) | 1999-11-29 | 2006-11-01 | Akzo Nobel Nv | 3-methylene steroid derivatives |
CA2412211A1 (en) * | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US7442765B2 (en) | 2000-08-24 | 2008-10-28 | Genentech, Inc. | Secreted transmembrane polypeptides and nucleic acids encoding the same |
US7265210B2 (en) | 2000-09-15 | 2007-09-04 | Genentech, Inc. | Anti-PRO9821 antibodies |
US7205392B2 (en) * | 2001-02-05 | 2007-04-17 | Innoventus Project Ab | Histidine-rich glycoprotein |
US20030224984A1 (en) * | 2001-06-20 | 2003-12-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US7164007B2 (en) | 2001-06-20 | 2007-01-16 | Genentech, Inc. | Anti-PR020044 antibodies |
FR2851249A1 (fr) * | 2003-02-17 | 2004-08-20 | Commissariat Energie Atomique | Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications |
NZ550110A (en) | 2004-04-14 | 2009-09-25 | Genentech Inc | Compositions and methods comprising an EGFL7 antagonist for modulating vascular development |
-
2005
- 2005-04-14 NZ NZ550110A patent/NZ550110A/en not_active IP Right Cessation
- 2005-04-14 CA CA2563445A patent/CA2563445C/en not_active Expired - Fee Related
- 2005-04-14 WO PCT/US2005/013658 patent/WO2005117968A2/en active Application Filing
- 2005-04-14 CN CN2012103813601A patent/CN102895663A/zh active Pending
- 2005-04-14 CN CN2005800195117A patent/CN1997394B/zh not_active Expired - Fee Related
- 2005-04-14 MX MXPA06011851A patent/MXPA06011851A/es active IP Right Grant
- 2005-04-14 AU AU2005249377A patent/AU2005249377A1/en not_active Abandoned
- 2005-04-14 ZA ZA200608615A patent/ZA200608615B/en unknown
- 2005-04-14 JP JP2007508646A patent/JP5599136B2/ja not_active Expired - Fee Related
- 2005-04-14 KR KR1020067021268A patent/KR101227817B1/ko active IP Right Grant
- 2005-04-14 RU RU2006140081/13A patent/RU2365382C2/ru not_active IP Right Cessation
- 2005-04-14 EP EP05804788A patent/EP1734998A2/en not_active Ceased
- 2005-04-14 BR BRPI0509420-8A patent/BRPI0509420A/pt not_active IP Right Cessation
-
2006
- 2006-09-27 IL IL178329A patent/IL178329A0/en active IP Right Grant
- 2006-10-12 US US11/546,760 patent/US20070031437A1/en not_active Abandoned
-
2009
- 2009-01-22 US US12/357,819 patent/US20090297512A1/en not_active Abandoned
- 2009-04-16 RU RU2009114508/15A patent/RU2009114508A/ru unknown
-
2010
- 2010-10-14 US US12/904,813 patent/US8790646B2/en not_active Expired - Fee Related
-
2011
- 2011-09-01 JP JP2011190733A patent/JP2011241230A/ja not_active Withdrawn
-
2013
- 2013-06-13 IL IL226899A patent/IL226899A0/en unknown
- 2013-09-24 JP JP2013196507A patent/JP2013256535A/ja not_active Withdrawn
- 2013-10-16 RU RU2013146239/15A patent/RU2013146239A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2011241230A (ja) | 2011-12-01 |
US20120003208A1 (en) | 2012-01-05 |
EP1734998A2 (en) | 2006-12-27 |
CA2563445C (en) | 2016-07-19 |
WO2005117968A2 (en) | 2005-12-15 |
CA2563445A1 (en) | 2005-12-15 |
IL226899A0 (en) | 2013-07-31 |
KR101227817B1 (ko) | 2013-01-29 |
CN1997394B (zh) | 2012-11-28 |
WO2005117968A3 (en) | 2006-06-08 |
JP5599136B2 (ja) | 2014-10-01 |
JP2013256535A (ja) | 2013-12-26 |
ZA200608615B (en) | 2008-05-28 |
IL178329A0 (en) | 2007-02-11 |
KR20070029687A (ko) | 2007-03-14 |
AU2005249377A1 (en) | 2005-12-15 |
RU2006140081A (ru) | 2008-05-20 |
US20090297512A1 (en) | 2009-12-03 |
US8790646B2 (en) | 2014-07-29 |
RU2009114508A (ru) | 2010-10-27 |
RU2365382C2 (ru) | 2009-08-27 |
CN1997394A (zh) | 2007-07-11 |
RU2013146239A (ru) | 2015-04-27 |
US20070031437A1 (en) | 2007-02-08 |
JP2007532685A (ja) | 2007-11-15 |
CN102895663A (zh) | 2013-01-30 |
NZ550110A (en) | 2009-09-25 |
MXPA06011851A (es) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509420A (pt) | método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico | |
TR200102499T2 (tr) | Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
ATE544866T1 (de) | Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung | |
IS6069A (is) | N-cýanómetýlamíð sem próteasalatar | |
CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
MXPA04005003A (es) | Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo. | |
ATE293691T1 (de) | Myostatin genpromoter und inhibierung dessen aktivierung | |
TNSN07203A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
WO2007029188A3 (en) | Method of using fabric care compositions to achieve a synergistic odor benefit | |
MXPA03011270A (es) | Uso de antagonistas rank para tratar cancer. | |
BRPI0414724A (pt) | combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit | |
BR0108980A (pt) | Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina | |
BR0111785A (pt) | Composições e métodos para tratamento de candidìase | |
WO2002041831A3 (en) | Inositol derivatives for increasing chloride secretion and inhibiting inflammation | |
HUP0401913A2 (hu) | Bromhidrosis kezelésére és megelőzésére szolgáló gyógyszerkészítmény | |
TR200302134T4 (tr) | 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı. | |
DE60130659D1 (de) | Therapeutische verbindungen und verfahren | |
MXPA02012209A (es) | Terapia combinada contra tumores que comprende derivados de bistamicina acriloilo substituida y agentes de alquilacion. | |
MXPA04011018A (es) | Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias. | |
BR0113886A (pt) | Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit | |
ZA200209835B (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites. | |
ATE390144T1 (de) | Behandlung von fibrosen | |
WO2000074667A3 (en) | Compositions active in telomere damage comprising a taxane and telomerase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 15A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 11/02/2020. |